To explore the potential drugs targeting eight NRGs for the treatment of DLBCL, we searched the DGIdb database, as shown in Additional file 6: Table S6, along with 50 approved therapeutic compounds targeting four genes (HIF1A, SPP1, CDH1, and CCL2). The gene discussed is SPP1; the disease is diffuse large B-cell lymphoma.